None listed
Conditions
Brief summary
Participants will inhale a 4mL radioaerosol in two positions in random order throughout the nebulisation period of 20 minutes: 1. Upright sitting: or 2. Alternate Side Lying: (alternated between left and right at each minute) After each nebulisation a gamma camera will perform a 20-minute deposition scan incorporating a 2-minute transmission scan to outline the three-dimensional margin of the lung fields. This data will be reconstructed to determine the distribution of the deposited radioaerosol in the lungs. A 15% improvement in uniformity of deposition is the proposed minimum difference that would make further investigation of the alternate side lying strategy worthwhile in patient populations. Significance of project: In many patient populations (eg, cystic fibrosis, HIV and bronchiectasis), the pattern of deposition of inhaled medication is poor and non-uniform. Typically the upper lobes receive a reduced dose compared to the rest of the lung. The ability to deliver a drug more uniformly to the lung using a strategy of side lying may have a significant impact on treatment efficacy for people with lung disease. Data from healthy participants will aid interpretation of subsequent studies in patients.
Interventions
Participants will inhale 4mL technetium-99m DTPA radioaerosol in two positions in random order throughout the nebulisation period of 20 minutes for each of the positioning regimens on two separte days: 1. Upright sitting: or 2. Alternate Side Lying: (alternated between left and right at each minute) The two study days will have a minimum of 48 hours washout between them and not greater than 7 days (to ensure clinical stability). After each nebulisation a gamma camera will perform a 20 minute deposition scan incorporating a 2 minute transmission scan to outline the three-dimensional margin of the lung fields. This data will be reconstructed to determine the distribution of the deposited radioaerosol in the lungs.
Sponsors
Study design
Eligibility
Inclusion criteria
Inclusion Criteria: To participate in this study, a person must: 1 be 18 years of age or older 2 be able to read, write and comprehend English 3 have normal lung function, with greater than or equal to 80% predicted FEV1 4 be willing to inhale a 4mL radioaerosol and undergo a 20-minute gamma scan, on two occasions.
Exclusion criteria
Exclusion Criteria: A person will be ineligible to participate in this study if s/he: 1 has any respiratory condition 2 has significant malignant, neurological or musculoskeletal conditions 3 is unable to perform spirometry reproducibly 4 is pregnant, or is sexually active and unwilling to use contraception during the study 5 is in a dependent relationship to any of the investigators, eg. student, junior staff.